Johnson & Johnson EBITDA Margin 2010-2024 | JNJ

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Johnson & Johnson (JNJ) over the last 10 years. The current EBITDA margin for Johnson & Johnson as of March 31, 2024 is .
Johnson & Johnson EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-03-31 $85.65B $29.63B 34.59%
2023-12-31 $85.16B $24.58B 28.86%
2023-09-30 $80.32B $22.71B 28.28%
2023-06-30 $78.97B $22.16B 28.06%
2023-03-31 $77.46B $20.44B 26.38%
2022-12-31 $79.99B $27.10B 33.87%
2022-09-30 $77.21B $25.56B 33.11%
2022-06-30 $80.55B $24.20B 30.04%
2022-03-31 $79.85B $25.07B 31.39%
2021-12-31 $78.74B $26.80B 34.04%
2021-09-30 $91.45B $27.34B 29.89%
2021-06-30 $89.19B $27.92B 31.30%
2021-03-31 $84.21B $25.09B 29.80%
2020-12-31 $82.58B $24.04B 29.11%
2020-09-30 $80.86B $26.55B 32.84%
2020-06-30 $80.50B $23.79B 29.55%
2020-03-31 $82.73B $26.98B 32.61%
2019-12-31 $82.06B $25.01B 30.48%
2019-09-30 $81.71B $24.12B 29.51%
2019-06-30 $81.33B $27.18B 33.42%
2019-03-31 $81.59B $25.33B 31.04%
2018-12-31 $81.58B $26.54B 32.54%
2018-09-30 $81.38B $26.03B 31.98%
2018-06-30 $80.68B $26.26B 32.55%
2018-03-31 $78.69B $25.42B 32.31%
2017-12-31 $76.45B $24.63B 32.22%
2017-09-30 $74.36B $25.51B 34.30%
2017-06-30 $72.53B $25.18B 34.72%
2017-03-31 $72.17B $25.04B 34.69%
2016-12-31 $71.89B $24.65B 34.29%
2016-09-30 $71.60B $23.99B 33.51%
2016-06-30 $70.88B $22.72B 32.06%
2016-03-31 $70.18B $23.42B 33.37%
2015-12-31 $70.07B $23.62B 33.71%
2015-09-30 $70.52B $22.47B 31.86%
2015-06-30 $71.88B $25.16B 35.00%
2015-03-31 $73.59B $25.09B 34.10%
2014-12-31 $74.33B $25.06B 33.71%
2014-09-30 $74.43B $25.21B 33.87%
2014-06-30 $73.54B $22.08B 30.03%
2014-03-31 $71.92B $21.28B 29.59%
2013-12-31 $71.31B $20.13B 28.23%
2013-09-30 $70.52B $20.39B 28.91%
2013-06-30 $69.99B $20.37B 29.11%
2013-03-31 $68.59B $17.50B 25.51%
2012-12-31 $67.22B $18.04B 26.83%
2012-09-30 $65.92B $15.16B 22.99%
2012-06-30 $64.87B $15.45B 23.82%
2012-03-31 $65.00B $16.75B 25.77%
2011-12-31 $65.03B $16.18B 24.88%
2011-09-30 $64.42B $17.96B 27.88%
2011-06-30 $63.40B $17.98B 28.36%
2011-03-31 $62.13B $18.71B 30.11%
2010-12-31 $61.59B $20.45B 33.20%
2010-09-30 $62.49B $20.74B 33.19%
2010-06-30 $62.59B $20.77B 33.18%
2010-03-31 $62.50B $20.77B 33.23%
2009-12-31 $61.90B $19.07B 30.81%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $371.206B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $823.023B 118.95
Novo Nordisk (NVO) Denmark $597.650B 45.92
Merck (MRK) United States $318.348B 57.92
AbbVie (ABBV) United States $306.572B 15.84
AstraZeneca (AZN) United Kingdom $245.438B 21.34
Novartis AG (NVS) Switzerland $222.244B 15.44
Pfizer (PFE) United States $167.731B 20.84
Sanofi (SNY) $129.321B 12.19
Innoviva (INVA) United States $1.098B 7.71